Orexo AB (FRA:C5G) Retained Earnings : €-172.94 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Orexo AB Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Orexo AB's retained earnings for the quarter that ended in Dec. 2024 was €-172.94 Mil.

Orexo AB's quarterly retained earnings stayed the same from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€0.00 Mil) but then declined from Sep. 2024 (€0.00 Mil) to Dec. 2024 (€-172.94 Mil).

Orexo AB's annual retained earnings declined from Dec. 2022 (€-150.81 Mil) to Dec. 2023 (€-159.67 Mil) and declined from Dec. 2023 (€-159.67 Mil) to Dec. 2024 (€-172.94 Mil).

Orexo AB Retained Earnings Historical Data

The historical data trend for Orexo AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Retained Earnings Chart

Orexo AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-123.52

-144.12

-150.81

-159.67

-172.94

Orexo AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-159.67	-	-	-	-172.94

Orexo AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Orexo AB (FRA:C5G) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Orexo AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

ORX:Sweden 0H19:UK C5G:Germany

Address

Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105

Website

https://www.orexo.com

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines